The reasons for re‐treatment beyond 96 weeks (n = 31) were ALT>ULN + HBV DNA > 2000 IU/mL (58%), ALT<ULN + HBV DNA > 2000 IU/mL (32%), patient preference (6%) and new diagnosis of HCC (3%). Here, GPT is linked to hepatocellular carcinoma.